Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-24 · accession 0001209191-23-013765 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-28 | 2023-02-27 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $287.48 | -354 | 56.8K | -0.6% | -$101.8K |
| 2023-02-28 | 2023-02-24 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $289.12 | -3,308 | 57.2K | -5% | -$956.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-27 | S | D | 51 | $288.33 | 56,825 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74). (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2023-02-27 | S | D | 283 | $287.20 | 56,876 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60). (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2023-02-24 | F | D | 3,308 | $289.12 | 57,159 | D | — | — | |
| 4 | Common | Common Stock | 2023-02-27 | S | D | 20 | $289.29 | 56,805 | D | — | — | (F5) Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40). (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |